Altogether, our study provides one potential mechanism by which the microbiome directly contributes to the development of autoimmunity and lays the groundwork for future mechanistic studies on the effect of indole on the IL-23/Th17 axis and autoantibody pathogenicity, and suggests potential for blocking indole production as a therapy for RA and SpA. This evidence concerns the gene IL23A and Autoimmunity.